Related Experiment Video
Updated: May 26, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
The Genitourinary Medical Oncology Workforce in the United States
David J Benjamin1, Arash Rezazadeh Kalebasty2
1Hoag Family Cancer Institute, Newport Beach, CA.
Objective:
To characterize the genitourinary medical oncology workforce in the United States.
Methods:
Utilizing the top cancer hospitals as ranked by US News & World Reports, genitourinary medical oncologists in each state of the United States were identified. Data including gender, race/ethnicity, site of medical education, and site of clinical practice were collected.
Results:
A total of 451 genitourinary medical oncologists are involved in clinical care in the United States. Of these medical oncologists, 399 (88.5%) practice in academic settings while 52 (11.5%) practice in community-based settings. 327 (72.5%) of genitourinary medical oncologists are male, while 124 (27.5%) are female. 17 (3.8%) genitourinary medical oncologists are from under-represented minority groups in medicine (Black, Hispanic, or Native American). 321 (71.2%) genitourinary medical oncologists received training at medical schools in the US, while 130 (28.8%) trained at medical schools abroad. The Northeast US has the most genitourinary medical oncologists with 150, followed by the South with 129, the West with 97, and the Midwest with 75. Of note, seven states, including Alaska, Delaware, Idaho, Maine, North Dakota, South Dakota, and Wyoming, have no identified genitourinary medical oncologist.
Conclusion:
Disparities based off gender, race/ethnicity, and geographic location of practice exist in the genitourinary medical oncology workforce in the United States.
Related Concept Videos
Treatment Resistant Cancers
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy

